High-dose subcutaneous immunoglobulins for the treatment of severe treatment-resistant polymyositis.

Abstract

Polymyositis is a rare debilitating condition characterized by chronic inflammation and muscle weakness. Standard treatments include corticosteroids and immunosuppressants; however, resistance to these regimens may develop. Intravenous immunoglobulins (IVIg) are thus recommended for patients with drug-resistant polymyositis. The patient presented a resistant polymyositis with severe muscle weakness, increasing dysphagia, and significant loss in weight. Subcutaneous immunoglobulins (SCIg) were initiated after failure of steroids and immunosuppressive drugs. SCIg was given twice per week (2 then 1.3 g/kg/month). Clinical recovery was observed within 2 months after the SCIg initiation. After several injections, the patient showed a progressive improvement in muscle strength. Serum creatine kinase activity decreased to normal levels, and dysphagia was resolved. The SC injections were generally well tolerated and good patient satisfaction was reported. This promising observation suggests that SCIg may be useful in active and refractory polymyositis.

• Authors: Cherin Patrick, Delain Jean-Christophe, Crave Jean-Charles, Cartry Odile
• Journal: Case reports in rheumatology (Case Rep Rheumatol) Vol. 2014 Pg. 458231 ( 2014) ISSN: 2090-6889 [Print] United States
• PMID: 25140268 (Publication Type: Journal Article)